4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded by Zacks Investment Research to Hold – Defense World

4D Molecular Therapeutics (NASDAQ:FDMT Get Rating) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.

Shares of NASDAQ FDMT traded down $0.26 on Monday, reaching $7.43. 187,167 shares of the company traded hands, compared to its average volume of 215,170. 4D Molecular Therapeutics has a fifty-two week low of $6.92 and a fifty-two week high of $36.14. The company has a 50 day moving average of $11.09 and a 200 day moving average of $15.39. The stock has a market capitalization of $239.99 million, a PE ratio of -2.68 and a beta of 1.61.

Several large investors have recently modified their holdings of the company. Royce & Associates LP acquired a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $204,000. Deep Track Capital LP acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at approximately $41,686,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at approximately $284,000. Goldman Sachs Group Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $261,000. Finally, Macquarie Group Ltd. acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $62,000. Institutional investors and hedge funds own 76.60% of the companys stock.

About 4D Molecular Therapeutics (Get Rating)

4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.

Read More

Get a free copy of the Zacks research report on 4D Molecular Therapeutics (FDMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

See the article here:
4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded by Zacks Investment Research to Hold - Defense World